Abstract
The identification of anaplastic lymphoma kinase (ALK), an oncogenetic driver mutation, in lung cancer has paved the way for a new era in the treatment of non-small cell lung cancer (NSCLC). Targeting ALK using tyrosine kinase inhibitors (TKI) has dramatically improved the prognosis of patients with ALK-rearranged NSCLC. However, most patients relapse on ALK-TKI therapy within a few years because of acquired resistance. One mechanism of acquiring resistance is a second mutation on the ALK gene, and the representative mutation is L1996M in the gatekeeper residue. In particular, the solvent-front ALK G1202R mutation is the common cause of resistance against first- and second-generation ALK-TKIs. Another major concern regarding ALK-TKI is metastasis to the central nervous system, commonly observed in patients relapsing after ALK-TKI therapy. The next-generation ALK inhibitor lorlatinib (PF-06463922) has therefore been developed to inhibit resistant ALK mutations, including ALK G1202R, and to penetrate the blood-brain barrier. In a Phase I/II trial, the safety and efficacy of lorlatinib were demonstrated in patients with advanced ALK-positive NSCLC, most of whom had central nervous system metastases and had previous ALK-TKI treatme...Continue Reading
Citations
Jun 30, 2019·Neurology·Alessia PellerinoRiccardo Soffietti
Nov 22, 2019·ESMO Open·Anastasia KougioumtziGeorge Pentheroudakis
May 31, 2020·Advances in Therapy·Yasushi GotoYuichiro Ohe
Nov 7, 2019·Frontiers in Oncology·Chang LiuJialei Wang
Jul 28, 2019·BMJ Case Reports·Huda GaferMichel van den Heuvel
Jul 25, 2019·Thoracic Cancer·Naoki HaratakeMitsuhiro Takenoyama
Dec 9, 2020·International Journal of Biological Macromolecules·Yuping ZhaoHafiz M N Iqbal
Jan 4, 2021·Cancer Treatment and Research Communications·Oranus MohammadiMohammad Jahanzeb
Feb 5, 2021·Frontiers in Oncology·Yalin KangXianglin Yuan
Jun 3, 2021·Journal of Medicinal Chemistry·Jennifer Alisa AmrheinThomas Hanke
Jun 4, 2021·PharmacoEconomics·Fredrik O L NilssonSarah Smith
Jun 11, 2021·Expert Review of Anticancer Therapy·Naoki HaratakeMasaki Mori
Jun 15, 2021·Respirology Case Reports·Kota SasakiAtsushi Sato
Sep 22, 2021·Cancer·Alina SadafJoseph G Pressey
Oct 1, 2021·PloS One·Yoko OtaHiroki Nagase